Rosetta Genomics is a leading molecular diagnostics company advancing minimally-invasive molecular tests based on its proprietary microRNAs, and platform technologies. Following the launch of three cancer tests in the beginning of 2009, the Company is now working to develop cancer screening products, including a colon cancer screening test.
November 17, 2009
Notice of annual general meeting of shareholders...More
November 5, 2009
Rosetta Genomics strengthens microRNA intellectual property position with reciept of additional patent...More
